Arecor Therapeutics PLC Change of Nominated Advisor and Joint Broker
January 09 2025 - 1:00AM
RNS Regulatory News
RNS Number : 6601S
Arecor Therapeutics PLC
09 January 2025
Arecor Therapeutics
plc
("Arecor"
or the "Group")
CHANGE OF NOMINATED ADVISOR
AND JOINT BROKER
Cambridge, UK,
9 January 2025: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that Singer Capital Markets
Advisory LLP has been appointed as the Company's Nominated Advisor
and Joint Broker with immediate effect.
-ENDS-
For more
information, please contact:
|
Arecor
Therapeutics plc
|
www.arecor.com
|
|
Dr Sarah Howell, Chief Executive
Officer
David Ellam, Interim Chief Financial
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
Singer Capital
Markets Advisory LLP (NOMAD and Joint Broker)
Phil Davies, Sam Butcher
|
Tel : +44 (0) 20 7496
3000
|
|
WG Partners
LLP (Joint Broker)
|
|
|
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes Spang
|
Tel: +44 (0)203 705 9321
|
|
|
|
|
ICR
Healthcare
|
|
|
Chris Gardner, David Daley, Lindsey
Neville
|
Tel: +44 (0) 20 3709 5700
Email: arecor@icrhealthcare.com
|
Notes to
Editors
About
Arecor
Arecor Therapeutics plc is a globally focused
biopharmaceutical company transforming patient care by bringing
innovative medicines to market through the enhancement of existing
therapeutic products. By applying our innovative proprietary
technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other
indications, as well as working with leading pharmaceutical and
biotechnology companies to deliver therapeutic products. The
Arestat™ platform is supported by an extensive patent
portfolio. For further details please see our website,
www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPSSLESAEISEEF
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jan 2024 to Jan 2025
